Trial
NCT02036476
Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Dana-Farber Cancer Institute
Collaborators
Exelixis
Condition
Merkel Cell Carcinoma
Intervention
Cabozantinib
Why stopped
Lack of accrual.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-05-09